GlaxoSmithKline, the only manufacturer of shingles vaccines in the region


DUBLIN, August 9, 2022 /PRNewswire/ — The “Investigation report on China Zoster Vaccine Market 2022-2031″ report has been added to from offer.

The commercial name of the shingles vaccine (recombinant shingles vaccine) is SHINGRIX, which was developed by GlaxoSmithKline. His product was first approved in China in 2020. The shingles vaccine is suitable for adults aged 50 and over to protect against shingles (herpes zoster). The recombinant shingles vaccine has been listed on the Chinese market. By July 2022GlaxoSmithKline Biologicals is the only manufacturer in China’s shingles vaccine market.

According to this market research, since shingles vaccine entered the Chinese market in 2020, its annual sales value has reached 19 million yuan($2.85 million), and its annual sales volume has reached nearly 12,000 doses. The prospects for development are therefore quite good.

According to the analysis, from 2022 to 2031, as the shingles vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement speed. Therefore, as the Shingles Vaccine market share will gradually increase, the sales and sales volume will also increase.

Topics Covered:

  • The impact of COVID-19 on China Zoster Vaccine Market
  • Sales volume and value of China Shingles vaccine 2020-2021
  • Sales Volume and Value of Shingles Vaccine by Regions in China 2020-2021
  • Competitive landscape of China Zoster Vaccine Market
  • shingles vaccine price in China
  • shingles vaccine price in China by regions in China
  • Analysis of factors affecting the development of China Zoster Vaccine Market
  • Prospect of China Zoster Vaccine Market from 2022 to 2031

Main topics covered:

1 Relevant shingles vaccine concepts
1.1 Indications for shingles vaccine
1.2 Development of the shingles vaccine in China
1.3 Government approval of the shingles vaccine China
1.4 The impact of COVID-19 on Herpes Zoster Vaccine sales in China

2 Herpes Zoster Vaccine Sales in China in 2020-2021
2.1 Zoster Vaccine Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Regions
2.2 Herpes Zoster Vaccine Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Herpes Zoster Vaccine Sales by Dosage Form in China in 2020-2021
2.3.1 Injection
2.3.2 Analysis of other dosage forms

3 Key Manufacturers Analysis of Herpes Zoster Vaccines China in 2020-2021
3.1 Herpes Zoster Vaccine Major Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 GlaxoSmithKline Biologics
3.2.1 Company Profile
3.2.2 SHINGRIX (GlaxoSmithKline Biologicals) Shingles Vaccine Sales in China

4 Herpes Zoster Vaccine Price for Different Manufacturers in China2021-2022
4.1 GlaxoSmithKline Biologicals (SHINGRIX)
4.2 Others

5 China Zoster Vaccine Market Outlook, 2022-2026
5.1 Influencing Factors on the Development of China Zoster Vaccine Market
5.1.1 The impact of COVID-19 on the Chinese shingles vaccine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies cited

  • GlaxoSmithKline Biologicals (SHINGRIX)

For more information on this report, visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716


SOURCE Research and Markets


Comments are closed.